Vaccines comprising aluminium adjuvants and histidine

Details Vaccines comprising aluminium adjuvants and histidine Vaccines comprising aluminium adjuvants and histidine

2008-03-25

2008-03-25

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C536S023100

Reexamination Certificate

active

10484702

ABSTRACT:
To improve the stability of vaccines comprising aluminum salt(s), the invention uses the amino acid histidine. This can improve pH stability and adjuvant adsorption and can be reduce antigen hydrolysis. Histidine is preferably presen during adsorption to the aluminium salt(s). The antigen in the vaccine may be a protein or a saccharide and is preferably fromN. meningitidis.

REFERENCES:
patent: 6472518 (2002-10-01), Ribot et al.
patent: 0835663 (1998-04-01), None
patent: WO 99 48525 (1999-09-01), None
patent: WO 00 57906 (2000-10-01), None
patent: WO 01 41800 (2001-06-01), None
Hommet al: “Assessment of the Stability and Immunogenicity of Meningococcal Oligosaccharide C-CRM197 Conjugate Vaccines”; Vaccine, Butterworth Scintific. Guildford, GB, vol. 19, No. 7-8, pp. 716-725, XP004225388, Nov. 22, 2000.

Affiliated with

Also associated with

Rating

Vaccines comprising aluminium adjuvants and histidine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccines comprising aluminium adjuvants and histidine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccines comprising aluminium adjuvants and histidine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3939718